Limits...
Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection.

Chirch LM, Steigbigel RT - Infect Drug Resist (2010)

Bottom Line: Raltegravir, an inhibitor of the HIV-1 integrase enzyme, is the first available agent in a new class of antiretroviral drugs.Raltegravir has been studied extensively in clinical trials, and has been well tolerated and highly effective in both treatment-naïve and -experienced patients.Resistance to raltegravir is unusual given its recent availability, but resistance with identified viral mutation pathways in the integrase gene in patients receiving the drug does occur.

View Article: PubMed Central - PubMed

Affiliation: Division of Infectious Diseases, Department of Medicine, Stony Brook University Medical Center, Stony Brook, New York, USA.

ABSTRACT
Raltegravir, an inhibitor of the HIV-1 integrase enzyme, is the first available agent in a new class of antiretroviral drugs. Raltegravir has been studied extensively in clinical trials, and has been well tolerated and highly effective in both treatment-naïve and -experienced patients. Resistance to raltegravir is unusual given its recent availability, but resistance with identified viral mutation pathways in the integrase gene in patients receiving the drug does occur.

No MeSH data available.


Percentage of patients with HIV RNA < 50 copies/mL at week 96 by genotypics sensitivity score (GSS).aCopyright © Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, N.J., USA. All Rights Reserved.*Virologic failures carried forward.Abbreviation: OBT, optimized background therapy.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3108745&req=5

f3-idr-3-015: Percentage of patients with HIV RNA < 50 copies/mL at week 96 by genotypics sensitivity score (GSS).aCopyright © Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, N.J., USA. All Rights Reserved.*Virologic failures carried forward.Abbreviation: OBT, optimized background therapy.

Mentions: Figure 3 depicts rates of viral suppression at week 96 stratified by GSS. As expected, patients with more active agents in their OBT had higher rates of virologic suppression in both the raltegravir and placebo arms (65% vs 53%, respectively, with a GSS of ≥2). The most dramatic difference was observed between arms in patients who had no active agents in their OBT, or a GSS of 0. These patients who received raltegravir had a rate of viral suppression to less than 50 copies/mL at 96 weeks of 41%, compared to 5% who received placebo plus OBT.22 Those who received either darunavir or enfuvirtide for the first time as part of their OBT also did significantly better than those who did not. The rates of virologic suppression in patients receiving both these agents in their OBT were similar between the two arms (79% on raltegravir, 63% on placebo), whereas patients with neither darunavir or enfuvirtide in their OBT did significantly better on raltegravir (56% suppressed to <50 copies/mL, compared to 19% on placebo).


Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection.

Chirch LM, Steigbigel RT - Infect Drug Resist (2010)

Percentage of patients with HIV RNA < 50 copies/mL at week 96 by genotypics sensitivity score (GSS).aCopyright © Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, N.J., USA. All Rights Reserved.*Virologic failures carried forward.Abbreviation: OBT, optimized background therapy.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3108745&req=5

f3-idr-3-015: Percentage of patients with HIV RNA < 50 copies/mL at week 96 by genotypics sensitivity score (GSS).aCopyright © Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, N.J., USA. All Rights Reserved.*Virologic failures carried forward.Abbreviation: OBT, optimized background therapy.
Mentions: Figure 3 depicts rates of viral suppression at week 96 stratified by GSS. As expected, patients with more active agents in their OBT had higher rates of virologic suppression in both the raltegravir and placebo arms (65% vs 53%, respectively, with a GSS of ≥2). The most dramatic difference was observed between arms in patients who had no active agents in their OBT, or a GSS of 0. These patients who received raltegravir had a rate of viral suppression to less than 50 copies/mL at 96 weeks of 41%, compared to 5% who received placebo plus OBT.22 Those who received either darunavir or enfuvirtide for the first time as part of their OBT also did significantly better than those who did not. The rates of virologic suppression in patients receiving both these agents in their OBT were similar between the two arms (79% on raltegravir, 63% on placebo), whereas patients with neither darunavir or enfuvirtide in their OBT did significantly better on raltegravir (56% suppressed to <50 copies/mL, compared to 19% on placebo).

Bottom Line: Raltegravir, an inhibitor of the HIV-1 integrase enzyme, is the first available agent in a new class of antiretroviral drugs.Raltegravir has been studied extensively in clinical trials, and has been well tolerated and highly effective in both treatment-naïve and -experienced patients.Resistance to raltegravir is unusual given its recent availability, but resistance with identified viral mutation pathways in the integrase gene in patients receiving the drug does occur.

View Article: PubMed Central - PubMed

Affiliation: Division of Infectious Diseases, Department of Medicine, Stony Brook University Medical Center, Stony Brook, New York, USA.

ABSTRACT
Raltegravir, an inhibitor of the HIV-1 integrase enzyme, is the first available agent in a new class of antiretroviral drugs. Raltegravir has been studied extensively in clinical trials, and has been well tolerated and highly effective in both treatment-naïve and -experienced patients. Resistance to raltegravir is unusual given its recent availability, but resistance with identified viral mutation pathways in the integrase gene in patients receiving the drug does occur.

No MeSH data available.